Drug intelligence / Profile preview

R&D113

Development stage: Unknown
Lead developer: Bostal Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

R&D113 is a long-acting injectable (LAI) antipsychotic formulation under development by Bostal Drug Delivery for the treatment of schizophrenia and bipolar I disorder. Developed via the 505(b)(2) regulatory pathway, R&D113 is designed to provide ultra-long-term therapeutic coverage with dosing intervals of six or eight months. This extended duration is intended to address the significant challenge of medication non-adherence in patients with chronic psychiatric conditions. As of 2024, the candidate is in the early stages of development, with Phase 1 clinical trials projected for 2027.

Other names: R&D113 LAI

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on R&D113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R&D113.

Explore the full profile